Lanini, Simone
,
Scognamiglio, Paola
Mecozzi, Alessandra
Lombardozzi, Lorella
Vullo, Vincenzo
Angelico, Mario
Gasbarrini, Antonio
Taliani, Gloria
Attili, Adolfo Francesco
Perno, Carlo Federico
De Santis, Adriano
Puro, Vincenzo
Cerqua, Fabio
D’Offizi, Gianpiero
Pellicelli, Adriano
Armignacco, Orlando
Mennini, Francesco Saverio
Siciliano, Massimo
Girardi, Enrico
Panella, Vincenzo
Ippolito, Giuseppe http://orcid.org/0000-0002-1076-2979
Funding for this research was provided by:
Regione Lazio Italy
Ministero della Salute (Ricerca corrente)
Article History
Received: 15 August 2017
Accepted: 30 April 2018
First Online: 16 May 2018
Ethics approval and consent to participate
: This study was carried out within the institutional mandate of the Lazio Region Health Authority to the Lazio Regional Service for Epidemiology and Surveillance of Infectious Diseases (SeRESMI). The terms of SeRESMI mandate and utilization of data collected are established by a Regional law and includes monitoring access to therapy with DAA, monitoring therapy outcome and implementation of periodical analyses for administrative and scientific purposes. Patients signed informed consent for use of anonymous information accordingly with the Regional act which has enforced the clinical network. Patients’ data were collected through an on-line system and only physicians who have patients in care had access to patients’ personal information. Patients received treatment according to clinical judgment, current availability of drugs and current guidelines at the time they started therapy. We have received the consent for publishing the information contained in the study by the ethics committee of INMI Lazzaro Spallanzani.
: CFP has received research grants, lecturing fees, advisory boards, scientific consultancies for Abbvie, Gilead Sciences, BMS, Janssen Cilag, VIIV, Roche, Abbott Diagnostics. EG has received personal fees from Gilead Sciences, Janssen, Otsuka Novel Products and Angelini for consultancy or lectures, outside the submitted work. GDO has received personal fees for Speaking, teaching and participation to advisory board for: Gilead, BMS, MSD. MA: has received grants for fellowship, research and participation to international meetings form Abbvie, Gilead, Janssen, MSD, he participated to advisory board for Gilead and Abbvie. GT: has received Traveling and speaking fees from Abbvie, BMS, Gilead, MSD. AP: has received grants for participation to meeting form: MSD, Gilead, Bristol Meyer Squibb. ADS: has received traveling and speaking fees from Abbvie and Gilead. AG: has received grants for fellowship, research and participation to international meetings form Abbvie, Gilead, Janssen, Alfa Wassermann, CD INV, Sigma Tau, Takeda, MSD; he participated to advisory board for Gilead, CD INV, Sigma Tau, Alfa Wassermann and Abbvie. FSM has received grants for fellowship, research and participation to international meetings form Abbvie, Gilead, Janssen, MSD; he participated to advisory board for Abbvie, Gilead, Janssen and MSD. GI, SL, VP, PS VV, MS, AM, LL, FC, OA, AFA, declare no competing interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.